Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 08, 2018 09:00 ET | Source: Chiasma, Inc.

Chiasma Reports on Significant Progress Made During 2017

Initiated CHIASMA OPTIMAL Phase 3 Clinical Trial after SPA agreement with FDAAnnounces expected year-end 2017 cash and investments balance of approximately $67 millionContinues to expect existing cash...
November 09, 2017 16:05 ET | Source: Chiasma, Inc.

Chiasma Reports Third Quarter 2017 Results

WALTHAM, Mass., Nov. 09, 2017 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ:CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic...
November 01, 2017 08:50 ET | Source: Chiasma, Inc.

Chiasma Recognizes Acromegaly Awareness Day

WALTHAM, Mass., Nov. 01, 2017 (GLOBE NEWSWIRE) -- Chiasma, Inc. (Nasdaq:CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic...
September 27, 2017 16:05 ET | Source: Chiasma, Inc.

Chiasma Announces First Patient Is Randomized in Phase 3 CHIASMA OPTIMAL Clinical Trial of Octreotide Capsules in Patients with Acromegaly

WALTHAM, Mass., Sept. 27, 2017 (GLOBE NEWSWIRE) -- Chiasma, Inc. (Nasdaq:CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic...
August 10, 2017 16:01 ET | Source: Chiasma, Inc.

Chiasma Reports Second Quarter 2017 Results

WALTHAM, Mass., Aug. 10, 2017 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ:CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic...
August 10, 2017 16:00 ET | Source: Chiasma, Inc.

Chiasma Reaches Agreement with FDA Under Special Protocol Assessment for a New Phase 3 Clinical Trial of Octreotide Capsules in Acromegaly

Chiasma plans to initiate enrollment in the new Phase 3 clinical trial – OPTIMAL – during second half of 2017Anticipates release of top-line data from new OPTIMAL trial by end of 2019Conference call...
June 19, 2017 08:18 ET | Source: Chiasma, Inc.

Chiasma Appoints Roni Mamluk, Ph.D. to Board of Directors

WALTHAM, Mass., June 19, 2017 (GLOBE NEWSWIRE) -- Chiasma, Inc. (Nasdaq:CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic...
May 05, 2017 08:00 ET | Source: Chiasma, Inc.

Chiasma Reports First Quarter 2017 Results

WALTHAM, Mass., May 05, 2017 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ:CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic...
March 30, 2017 16:05 ET | Source: Chiasma, Inc.

Chiasma Announces Poster Presentation at ENDO 2017 on Evaluation of Acromegaly Symptoms from the Newly Developed Acromegaly Treatment Satisfaction Questionnaire

WALTHAM, Mass., March 30, 2017 (GLOBE NEWSWIRE) -- Chiasma, Inc. (Nasdaq:CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic...
March 16, 2017 16:05 ET | Source: Chiasma, Inc.

Chiasma Reports Fourth Quarter and Year End 2016 Results

WALTHAM, Mass., March 16, 2017 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ:CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic...